Xilio Therapeutics, Inc.

XLO

US98422T1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
1.07 ^USD	-6.96%		0.00%	+96.36%

05-14	Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-19	Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	MT

Xilio Therapeutics, Inc. Announces Resignation of Salvatore Giovine as Chief Financial Officer Effective August 19, 2022

July 28, 2022 at 10:07 pm

Salvatore Giovine notified Xilio Therapeutics, Inc. of his decision to resign as chief financial officer of the Company, effective August 19, 2022, for personal family reasons.

Latest news about Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Gilead Sciences Likely to Record IPR&D Hit on Q1 Non-GAAP Earnings, Oppenheimer Says	04-19	MT
Xilio Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	04-01	CI
Xilio Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Sector Update: Health Care Stocks Slide Late Afternoon	04-01	MT
Top Midday Gainers	04-01	MT
Signs of Softening Inflation Fuel Narrow Premarket Gains for US Equity Futures	04-01	MT
Top Premarket Gainers	04-01	MT
Xilio Shares Take Flight Premarket After Gilead Deal	03-28	DJ
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	03-28	MT
Gilead Sciences Signs Exclusive Development, Commercialization License for Xilio's Tumor-Activated IL-12	03-28	MT
Transcript : Xilio Therapeutics, Inc. - Special Call	03-28
Xilio Therapeutics Plans Private Placement, Job Cuts	03-28	DJ
Gilead Sciences in Exclusive License for Xilio Tumor-Activated IL-12 Program	03-28	DJ
Xilio Therapeutics, Inc. Enters Exclusive License Agreement with Gilead Sciences, Inc	03-28	CI
Xilio Therapeutics, Inc. Plans Workforce Reduction	03-28	CI
Xilio Therapeutics, Inc. Reports Additional Data from Its Phase 2 Clinical Trial Evaluating XTX202	03-28	CI
Xilio Therapeutics, Inc. announced that it expects to receive $11.3 million in funding	03-27	CI
Xilio Therapeutics, Inc. Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101	12-07	CI
Xilio Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Transcript : Xilio Therapeutics, Inc. - Special Call	11-06
Xilio Therapeutics Shares Rise Following Initial Phase 1/2 Data on XTX202	11-03	MT
Xilio Therapeutics, Inc. Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202	11-03	CI
Transcript : Xilio Therapeutics, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 02:55 PM	11/09/23
Xilio Therapeutics Announces Board Changes	05/09/23	CI

Chart Xilio Therapeutics, Inc.

Duration

Period

More charts

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The Company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers). Its product pipeline includes XTX101, XTX301, XTX202, XTX501, and tumor-activated bispecific molecules and immune cell engager molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Sector

Biotechnology & Medical Research

Calendar

01/06/2024 - American Society of Clinical Oncology Annual Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.15 USD

Average target price

4.667 USD

Spread / Average Target

+305.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
XILIO THERAPEUTICS, INC.	+96.36%	42.44M
MODERNA, INC.	+64.92%	62.59B
IQVIA HOLDINGS INC.	-1.87%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+12.83%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.89%	19.09B
BIO-TECHNE CORPORATION	+4.12%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B
MEDPACE HOLDINGS, INC.	+27.16%	12.05B

Other Biotechnology & Medical Research